The sponsors of testosterone replacement therapies may have to conduct additional studies to assess both the potential cardiovascular risk of these products and to show that they actually benefit the primary population using the drugs, according to FDA briefing documents for an upcoming advisory committee meeting.
Testosterone Makers May Have To Do CV Risk Studies, Prove Benefit For ‘Low T’ Use
FDA says current epidemiological studies do not provide “convincing evidence” the products are either particularly helpful or harmful for treatment of aging men with low testosterone.
More from Post-Marketing Regulation & Studies
More from Product Reviews
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.
• By
The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.